KDR and hepatocellular carcinoma: For instance, the multikinase inhibitor sorafenib reduces tumor cell proliferation and angiogenesis in HCC, which is due in part to its interaction with receptors for several growth factors, such as EGF (EGFR), VEGF (VEGFR) and PDGF (PDGFR)[6].